Hormonal contraceptive Access via Pharmacist-Prescribing Implementation package (HAPPI)

项目摘要/摘要 在美国，95%的意外怀孕都是错误的， 不一致或不使用避孕措施，改善获得可靠避孕措施的机会是一种 重要的公共卫生问题。药剂师被认为是最容易获得的医疗保健 并处于有利地位，通过提供药剂师- 规定的避孕服务。这项拟议工作的重点是药剂师，他们可以 提供最大的通道-那些在社区药店。有超过67,750个 美国的社区药房目前只有3500家提供药剂师 开避孕药处方。研究一致地确定了实施 药剂师开避孕药处方。为了最大限度地获得避孕药具， 药剂师的实施必须得到解决。 该项目将通过药剂师描述开发荷尔蒙避孕途径 实施(HAPPI)一揽子计划，将支持有效和可持续地提供 药剂师开的避孕药方服务。我们将使用融合的并行设计 包括定量和定性数据，以实现科学为基础 执行研究综合框架(CFIR)和循证质量 改进(EBQI)。混合方法方法将更好地为开发和 完善HAPPI一揽子计划。现有技术、工具和资源的摘要 可以用来、需要和/或考虑用来克服经常引用的障碍 实行药师处方避孕服务。模范采用者 将创建案例研究，以说明“最佳做法”。药房决策者(所有者 和管理人员)和最终用户(药房经理药剂师和员工药剂师)将 参加概念图的焦点小组和多方利益相关者咨询小组。这个 重点小组将确定HAPPI一揽子计划中包含的工具和资源并确定其优先顺序 虽然多方利益攸关方咨询小组将就感知的可接受性提供意见， 实施药剂师处方避孕服务的适当性和可行性 无论有没有HAPPI套餐。 药剂师开避孕药处方有可能扩大获得 避孕。如果成功，该项目将创建一个原型实现包，将 形成我们未来SBIR第二阶段拨款的基础，以进行可用性测试，并最终 将HAPPI一揽子计划商业化并衡量其影响。

Project Summary/Abstract With 95% of unintended pregnancies in the United States attributed to incorrect, inconsistent, or non-use of contraception, improving access to reliable contraception is an important public health issue. Pharmacists are considered the most accessible health care provider and are well-positioned to improve contraception access by providing pharmacist- prescribed contraception services. The focus of this proposed work is on pharmacists who can provide greatest access – those in community pharmacies. There are more than 67,750 community pharmacies in the United States and only 3,500 are currently offering pharmacist prescribing of contraception. Research consistently identifies barriers to implementation of pharmacist contraception prescribing. In order to maximize access to contraception, barriers to pharmacist implementation must be addressed. This project will develop a Hormonal contraceptive Access via Pharmacist-Prescribing Implementation (HAPPI) package that will support effective and sustainable provision of pharmacist-prescribed contraception services. We will use a convergent, parallel design including both quantitative and qualitative data, grounded in implementation science using the Consolidated Framework for Implementation Research (CFIR) and Evidence-Based Quality Improvement (EBQI). The mixed methods approach will better inform development and refinement of the HAPPI package. A summary of the existing technology, tools, and resources that may be used, needed, and/or considered to overcome frequently cited barriers to the implementation of pharmacist-prescribed contraception services will be created. Model adopter case studies will be created to illustrate “best practices”. Pharmacy decision makers (owners and executives) and end-users (pharmacy manager pharmacists and staff pharmacists) will participate in focus groups for concept mapping and a multi-stakeholder advisory panel. The focus groups will identify and prioritize tools and resources to be included in the HAPPI package while the multi-stakeholder advisory panel will provide input on perceived acceptability, appropriateness, and feasibility of implementing pharmacist-prescribed contraception services with and without the HAPPI package. Pharmacist contraceptive prescribing has the potential to expand access to contraception. If successful, this project will create a prototype implementation package that will form the basis for our future SBIR Phase II grant to conduct usability testing and ultimately commercialize and measure the impact of the HAPPI package.